Appreciation of trimetazidine treatment in experimental sepsis rat model

Introduction: Our aim was to determine the efficacy of trimetazidine on experimental sepsis rat model

Supplementary Material for: Protective effect of glutathione administration on ovarian function in female rats with cyclophosphamide-induced ovarian damage

Objectives: We investigated the potential of glutathione to protect ovarian function in rats exposed to cyclophosphamide by measuring serum anti-Mullerian hormone levels, follicle counts, and related parameters. Design: Forty-two adult female Sprague-Dawley rats were randomly divided into six groups and treated with various combinations of cyclophosphamide, glutathione, and sodium chloride. On day 21, the rats were anaesthetized, and their ovaries were removed for examination. Participants/Materials, Setting, Methods: Histopathological examination, serum anti-Mullerian hormone (AMH) concentrations, follicle counts, anti-Mullerian hormone-positive staining of follicle percentages were analyzed. Statistical analysis was performed using a one-way analysis of variance and Tukey’s test, with significance set at p<0.05. Primary evaluations included serum anti-Mullerian hormone concentrations and ovarian follicle counts. Secondary measures encompassed histopathological examination and percentages of anti-Mullerian hormone-positive staining of follicles. Results Significant differences were observed in follicle counts, anti-Mullerian hormone-positive follicle parameters, and serum anti-Mullerian hormone concentrations among the six groups. Group 2 (treated with cyclophosphamide) had the lowest primordial, primary, secondary, and antral follicle counts and the highest atretic count. Group 6, treated with cyclophosphamide and 200 mg/kg glutathione, showed improved follicle counts compared to those in group 2. Reducing the glutathione dose to 100 mg/kg was ineffective. Limitations This was an experimental animal investigation with a comparatively modest sample size. Experimental studies should be conducted to determine the optimal dosage and duration of glutathione therapy. Information gathered from an experimental animal model may not yield precisely similar outcomes in humans; therefore, additional investigations are necessary to examine the impact of glutathione on women experiencing POI. Conclusions The anti-oxidative protective effect of directly administered glutathione was demonstrated for the first time. Low-dose glutathione was ineffective, whereas a high dose yielded significant ovarian protection against cyclophosphamide. Our findings provide valuable insights for supplementing clinical trials on the protective effects of glutathione against ovarian damage

Supplementary Material for: Protective effect of glutathione administration on ovarian function in female rats with cyclophosphamide-induced ovarian damage

Objectives: We investigated the potential of glutathione to protect ovarian function in rats exposed to cyclophosphamide by measuring serum anti-Mullerian hormone levels, follicle counts, and related parameters. Design: Forty-two adult female Sprague-Dawley rats were randomly divided into six groups and treated with various combinations of cyclophosphamide, glutathione, and sodium chloride. On day 21, the rats were anaesthetized, and their ovaries were removed for examination. Participants/Materials, Setting, Methods: Histopathological examination, serum anti-Mullerian hormone (AMH) concentrations, follicle counts, anti-Mullerian hormone-positive staining of follicle percentages were analyzed. Statistical analysis was performed using a one-way analysis of variance and Tukey’s test, with significance set at p<0.05. Primary evaluations included serum anti-Mullerian hormone concentrations and ovarian follicle counts. Secondary measures encompassed histopathological examination and percentages of anti-Mullerian hormone-positive staining of follicles. Results Significant differences were observed in follicle counts, anti-Mullerian hormone-positive follicle parameters, and serum anti-Mullerian hormone concentrations among the six groups. Group 2 (treated with cyclophosphamide) had the lowest primordial, primary, secondary, and antral follicle counts and the highest atretic count. Group 6, treated with cyclophosphamide and 200 mg/kg glutathione, showed improved follicle counts compared to those in group 2. Reducing the glutathione dose to 100 mg/kg was ineffective. Limitations This was an experimental animal investigation with a comparatively modest sample size. Experimental studies should be conducted to determine the optimal dosage and duration of glutathione therapy. Information gathered from an experimental animal model may not yield precisely similar outcomes in humans; therefore, additional investigations are necessary to examine the impact of glutathione on women experiencing POI. Conclusions The anti-oxidative protective effect of directly administered glutathione was demonstrated for the first time. Low-dose glutathione was ineffective, whereas a high dose yielded significant ovarian protection against cyclophosphamide. Our findings provide valuable insights for supplementing clinical trials on the protective effects of glutathione against ovarian damage

Supplementary Material for: Protective effect of glutathione administration on ovarian function in female rats with cyclophosphamide-induced ovarian damage

Objectives: We investigated the potential of glutathione to protect ovarian function in rats exposed to cyclophosphamide by measuring serum anti-Mullerian hormone levels, follicle counts, and related parameters. Design: Forty-two adult female Sprague-Dawley rats were randomly divided into six groups and treated with various combinations of cyclophosphamide, glutathione, and sodium chloride. On day 21, the rats were anaesthetized, and their ovaries were removed for examination. Participants/Materials, Setting, Methods: Histopathological examination, serum anti-Mullerian hormone (AMH) concentrations, follicle counts, anti-Mullerian hormone-positive staining of follicle percentages were analyzed. Statistical analysis was performed using a one-way analysis of variance and Tukey’s test, with significance set at p<0.05. Primary evaluations included serum anti-Mullerian hormone concentrations and ovarian follicle counts. Secondary measures encompassed histopathological examination and percentages of anti-Mullerian hormone-positive staining of follicles. Results Significant differences were observed in follicle counts, anti-Mullerian hormone-positive follicle parameters, and serum anti-Mullerian hormone concentrations among the six groups. Group 2 (treated with cyclophosphamide) had the lowest primordial, primary, secondary, and antral follicle counts and the highest atretic count. Group 6, treated with cyclophosphamide and 200 mg/kg glutathione, showed improved follicle counts compared to those in group 2. Reducing the glutathione dose to 100 mg/kg was ineffective. Limitations This was an experimental animal investigation with a comparatively modest sample size. Experimental studies should be conducted to determine the optimal dosage and duration of glutathione therapy. Information gathered from an experimental animal model may not yield precisely similar outcomes in humans; therefore, additional investigations are necessary to examine the impact of glutathione on women experiencing POI. Conclusions The anti-oxidative protective effect of directly administered glutathione was demonstrated for the first time. Low-dose glutathione was ineffective, whereas a high dose yielded significant ovarian protection against cyclophosphamide. Our findings provide valuable insights for supplementing clinical trials on the protective effects of glutathione against ovarian damage

Supplementary Material for: Protective effect of glutathione administration on ovarian function in female rats with cyclophosphamide-induced ovarian damage

Objectives: We investigated the potential of glutathione to protect ovarian function in rats exposed to cyclophosphamide by measuring serum anti-Mullerian hormone levels, follicle counts, and related parameters. Design: Forty-two adult female Sprague-Dawley rats were randomly divided into six groups and treated with various combinations of cyclophosphamide, glutathione, and sodium chloride. On day 21, the rats were anaesthetized, and their ovaries were removed for examination. Participants/Materials, Setting, Methods: Histopathological examination, serum anti-Mullerian hormone (AMH) concentrations, follicle counts, anti-Mullerian hormone-positive staining of follicle percentages were analyzed. Statistical analysis was performed using a one-way analysis of variance and Tukey’s test, with significance set at p<0.05. Primary evaluations included serum anti-Mullerian hormone concentrations and ovarian follicle counts. Secondary measures encompassed histopathological examination and percentages of anti-Mullerian hormone-positive staining of follicles. Results Significant differences were observed in follicle counts, anti-Mullerian hormone-positive follicle parameters, and serum anti-Mullerian hormone concentrations among the six groups. Group 2 (treated with cyclophosphamide) had the lowest primordial, primary, secondary, and antral follicle counts and the highest atretic count. Group 6, treated with cyclophosphamide and 200 mg/kg glutathione, showed improved follicle counts compared to those in group 2. Reducing the glutathione dose to 100 mg/kg was ineffective. Limitations This was an experimental animal investigation with a comparatively modest sample size. Experimental studies should be conducted to determine the optimal dosage and duration of glutathione therapy. Information gathered from an experimental animal model may not yield precisely similar outcomes in humans; therefore, additional investigations are necessary to examine the impact of glutathione on women experiencing POI. Conclusions The anti-oxidative protective effect of directly administered glutathione was demonstrated for the first time. Low-dose glutathione was ineffective, whereas a high dose yielded significant ovarian protection against cyclophosphamide. Our findings provide valuable insights for supplementing clinical trials on the protective effects of glutathione against ovarian damage

Tanoglu, Analysis of the corner layer problem in anisotropy, Discrete Continuous Dyn

Abstract. We investigate a model of anisotropic diffuse interfaces in ordered FCC crystals introduced recently by Braun et al and Tanoglu et al [BCMcFW, T, TBCMcF], focusing on parametric conditions which give extreme anisotropy. For a reduced model, we prove existence and stability of plane wave solutions connecting the disordered FCC state with the ordered Cu3Au state described by solutions to a system of three equations. These plane wave solutions correspond to planar interfaces. Different orientations of the planes in relation to the crystal axes give rise to different surface energies. Guided by previous work based on numerics and formal asymptotics, we reduce this problem in the six dimensional phase space of the system to a two dimensional phase space by taking advantage of the symmetries of the crystal and restricting attention to solutions with corresponding symmetries. For this reduced problem a standing wave solution is constructed that corresponds to a transition that, in the extreme anisotropy limit, is continuous but not differentiable. We also investigate the stability of the constructed solution by studying the eigenvalue problem for the linearized equation. We find that although the transition is stable, there is a growing number 0 ( 1 1 ǫ), of critical eigenvalues, where ǫ ≫ 1 is a measure of the anisotropy. Specifically we obtain a discrete spectrum with eigenvalues λn = ǫ2/3 µn with µn ∼ Cn2/3, as n → +∞. The scaling characteristics of the critical spectrum suggest a previously unknown microstructural instability